FARE | Food Allergy Research & Education @FoodAllergy · 28 Aug 2026
For the more than 470,000 people in the U.S. living with EoE, we wanted to share some encouraging news. Newly announced Phase 3 results for tezepelumab-ekko showed improvements in swallowing symptoms and other signs of the disease. Read more about the phase 3 trial results here: https://t.co/NkuylOYiqk
492Views
1Likes
0Reposts
0Replies
0Quotes
0Bookmarks
Is that a lot?
0.61×vs this author's median812 views is typical
0Percentile for this authorof 5 recent posts
0.34×vs 10K–100K median1 456 views is typical
2.12%Reachviews ÷ followers
0.20%Engagement rateof viewers reacted